Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Co. stock logo
ABSI
Absci
$2.48
+3.3%
$3.82
$2.29
$6.72
$315.79M2.092.45 million shs3.37 million shs
Elevance Health, Inc. stock logo
ELV
Elevance Health
$429.36
-0.8%
$407.13
$362.21
$567.26
$97.20B0.771.39 million shs1.16 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$819.57
+1.8%
$848.85
$711.40
$972.53
$777.09B0.343.31 million shs2.68 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$68.20
+0.2%
$81.64
$66.33
$148.15
$306.05B0.425.59 million shs7.30 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$25.68
+7.4%
$29.77
$23.27
$81.86
$2.88B0.93.90 million shs4.40 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Co. stock logo
ABSI
Absci
-4.38%-21.82%-37.66%-8.40%-57.22%
Elevance Health, Inc. stock logo
ELV
Elevance Health
-0.56%+2.36%+9.05%+17.38%-16.07%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.63%-5.71%-12.68%+4.11%+5.76%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.27%-7.57%-25.00%-20.95%-46.69%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-0.99%-14.55%-17.18%-40.58%-69.92%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Absci Co. stock logo
ABSI
Absci
2.4015 of 5 stars
3.53.00.00.02.60.80.6
Elevance Health, Inc. stock logo
ELV
Elevance Health
4.6525 of 5 stars
3.53.04.20.04.22.52.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8097 of 5 stars
2.45.03.34.03.32.51.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.8344 of 5 stars
4.45.02.50.02.00.04.4
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.3443 of 5 stars
4.51.00.04.72.03.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Absci Co. stock logo
ABSI
Absci
3.00
Buy$7.60206.45% Upside
Elevance Health, Inc. stock logo
ELV
Elevance Health
2.94
Moderate Buy$519.8121.07% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7223.20% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.80
Moderate Buy$145.25112.98% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$95.18270.65% Upside

Current Analyst Ratings Breakdown

Latest VKTX, LLY, NVO, ABSI, and ELV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/28/2025
Elevance Health, Inc. stock logo
ELV
Elevance Health
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
3/26/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
3/20/2025
Absci Co. stock logo
ABSI
Absci
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/19/2025
Absci Co. stock logo
ABSI
Absci
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
3/19/2025
Absci Co. stock logo
ABSI
Absci
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
3/17/2025
Elevance Health, Inc. stock logo
ELV
Elevance Health
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$450.00
3/13/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
3/11/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
3/3/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Absci Co. stock logo
ABSI
Absci
$4.53M69.65N/AN/A$1.90 per share1.31
Elevance Health, Inc. stock logo
ELV
Elevance Health
$176.81B0.55$43.07 per share9.97$178.62 per share2.40
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.25$13.36 per share61.34$15.05 per share54.46
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$290.40B1.05$3.16 per share21.57$4.64 per share14.70
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$3.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Absci Co. stock logo
ABSI
Absci
-$110.57M-$0.93N/AN/AN/A-2,321.56%-46.56%-39.74%5/13/2025 (Estimated)
Elevance Health, Inc. stock logo
ELV
Elevance Health
$5.98B$25.6116.7711.001.183.38%18.28%6.72%4/22/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7169.9926.341.4023.51%85.24%16.19%5/1/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.2920.7314.640.9034.81%84.68%26.29%5/1/2025 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.00N/AN/AN/AN/A-11.93%-11.57%4/23/2025 (Estimated)

Latest VKTX, LLY, NVO, ABSI, and ELV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/23/2025N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.34N/AN/AN/AN/AN/A
4/22/2025N/A
Elevance Health, Inc. stock logo
ELV
Elevance Health
$10.60N/AN/AN/A$46.26 billionN/A
3/18/2025Q4 2024
Absci Co. stock logo
ABSI
Absci
-$0.22-$0.25-$0.03-$0.25$1.77 million$0.67 million
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.88$0.91+$0.03$0.91N/AN/A
2/5/2025Q4 2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.27-$0.32-$0.05-$0.32N/AN/A
1/23/2025Q4 2024
Elevance Health, Inc. stock logo
ELV
Elevance Health
$3.80$3.84+$0.04$1.81$44.63 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Absci Co. stock logo
ABSI
Absci
N/AN/AN/AN/AN/A
Elevance Health, Inc. stock logo
ELV
Elevance Health
$6.841.59%+12.99%26.71%14 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%+15.21%51.24%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.572.30%+25.26%47.72%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest VKTX, LLY, NVO, ABSI, and ELV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.78741.2%3/31/20253/31/20254/8/2025
1/22/2025
Elevance Health, Inc. stock logo
ELV
Elevance Health
quarterly$1.711.75%3/10/20253/10/20253/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Absci Co. stock logo
ABSI
Absci
0.01
5.63
5.63
Elevance Health, Inc. stock logo
ELV
Elevance Health
0.71
1.45
1.50
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
36.47
36.47

Institutional Ownership

CompanyInstitutional Ownership
Absci Co. stock logo
ABSI
Absci
52.05%
Elevance Health, Inc. stock logo
ELV
Elevance Health
89.24%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Absci Co. stock logo
ABSI
Absci
9.81%
Elevance Health, Inc. stock logo
ELV
Elevance Health
0.35%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Absci Co. stock logo
ABSI
Absci
210127.33 million103.59 millionOptionable
Elevance Health, Inc. stock logo
ELV
Elevance Health
102,300226.39 million231.11 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.25 million106.20 millionOptionable

Recent News About These Companies

Viking Therapeutics Sees Unusually High Options Volume (NASDAQ:VKTX)
Modern medical technology system and devices - stock image
Which Healthcare Stock Is the Best Buy Right Now?
Viking Therapeutics completes enrollment in Phase 2 trial of VK2735

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Absci stock logo

Absci NASDAQ:ABSI

$2.48 +0.08 (+3.33%)
Closing price 04:00 PM Eastern
Extended Trading
$2.38 -0.10 (-4.03%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Elevance Health stock logo

Elevance Health NYSE:ELV

$429.36 -3.32 (-0.77%)
Closing price 03:58 PM Eastern
Extended Trading
$423.38 -5.98 (-1.39%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$819.57 +14.34 (+1.78%)
Closing price 03:58 PM Eastern
Extended Trading
$796.56 -23.02 (-2.81%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$68.20 +0.17 (+0.25%)
Closing price 03:58 PM Eastern
Extended Trading
$66.53 -1.67 (-2.45%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$25.68 +1.77 (+7.40%)
Closing price 04:00 PM Eastern
Extended Trading
$24.03 -1.65 (-6.43%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.